Valspodar

Drug Profile

Valspodar

Alternative Names: Amdray; PSC 833; SDZ PSC 833

Latest Information Update: 12 Sep 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antineoplastics
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Cancer; Multiple myeloma; Ovarian cancer; Renal cancer

Most Recent Events

  • 12 Sep 2001 A phase I/II trial has been added to the pharmacokinetics and Cancer therapeutic trials sections
  • 19 Apr 2001 Discontinued-II for Breast cancer in USA (PO)
  • 19 Apr 2001 Discontinued-II for Renal cancer in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top